213 filings
Page 5 of 11
D
qk08ia
29 Nov 21
$36.52M in equity, sold $16.12M, 26 investors
4:20pm
8-K
9jb 03kb341
15 Nov 21
Kala Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update
8:59am
8-K
1mckty
18 Oct 21
Departure of Directors or Certain Officers
8:05am
8-K
p95sw 0qmwo
5 Aug 21
Kala Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Update
7:01am
CT ORDER
q6ka29htuex48kj
15 Jul 21
Confidential treatment order
12:00am
8-K
x42zyw33
21 Jun 21
Submission of Matters to a Vote of Security Holders
4:01pm
8-K
tgpp7 wuxjy
5 May 21
Kala Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update
7:04am
8-K
1s176 h8u
5 May 21
Entry into a Material Definitive Agreement
7:00am
DEFA14A
kr9w936nvp7vz8k22
28 Apr 21
Additional proxy soliciting materials
8:03am
S-8
qijwh6r3dho2opy
25 Feb 21
Registration of securities for employees
4:10pm
8-K
tpo zog9wftyapnm5t7l
25 Feb 21
Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
7:01am
8-K
dtv8x3kama 1hnxtm4
7 Jan 21
Results of Operations and Financial Condition
7:02am
8-K
yttxrwie6i jd
5 Nov 20
Kala Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Corporate Update
7:01am
8-K
mmq51mx
27 Oct 20
Kala Pharmaceuticals Announces FDA Approval of EYSUVIS™ for the Short-Term Treatment of the Signs and Symptoms of Dry Eye Disease
7:03am